Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q2 2024 Earnings Presentation
15 slides from Q-linea Ab's earnings presentation, Jul 11, 2024
Slide 1: Presentation Q2(24)
Sustainable healthcare for a new generation Presentation Q2(24) July 11, 2024
Slide 2: Disclaimer
Disclaimer THIS PERESNTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. T
Slide 3: Key messages for today
Key messages for today US market now in full commercial mode with focus on early 1 adopters and leading lab facilities Geographic footprint expansion is proceeding thoughtfully 2 with prospective distribution partners across EMEA / RoW 3 Cost saving program successfully completed and will generate r
Slide 4: Q2 highlights: Full speed on commercialisation agenda with emphasis in USA
Q2 highlights| Full speed on commercialisation agenda with emphasis in USA Four overall areas of focus and progress during the quarter • First instruments shipped to US with market-specific settings & software; evaluations planned for July & August Commercial • CMS recommendation for NTAP reimbursem
Slide 5: ASTar: Revolutionizing AST
ASTar: Revolutionizing AST ~6 ~2 1st Hours Minutes Fully-automated, turn-around time Hands-on time random access platform ➢ Save lives ➢ Simple interface ➢ Comprehensive menu ➢ Save money ➢ Load-and-Go ➢ High reproducibility ➢ Reduced effort ➢ Minimal training need ➢ High throughput with 12 samples
Slide 6: Live in the USA! FDA clearance for ASTar awarded on April 26, 2024
Live in the USA! | FDA clearance for ASTar awarded on April 26, 2024 Comprehensive panel with 18 antibiotics and 12 microbial species; 7 – 11 two-fold dilutions per antibiotic ASTar v1 US menu The ASTar AST disc: 336 reaction wells in a 120 mm CD format. 10 different sectors Enables unparalleled fle
Slide 7: Segmentation is key especially for initial launch phase
US market | Segmentation is key especially for initial launch phase Locations of largest hospital labs, reference labs and IDNs across US FOCUS on the largest labs with proven track record of early adoption (50 – 100 centres) ENGAGE with thought leaders (KOLs) and decision makers at these institutio
Slide 8: ASM 2024: Opportunity for Q-linea to engage with US stakeholders
ASM 2024 | Opportunity for Q-linea to engage with US stakeholders Primary Microbiology conference in US held in Atlanta during June • >5,500 practitioners and decision makers from across the US • Rapid AST a key theme throughout clinical seminar sessions and scientific posters • Q-linea hosted poste
Slide 9: Leveraging the clinical evidence: Early results very strong, more studies coming
Leveraging the clinical evidence | Early results very strong, more studies coming Q-linea sponsored studies generating strong initial results Preliminary LIFETIMES study results Presented at the AMCLI Congress (Mar 2024), ESCMID (Apr 2024) and ASM (Jun 2024) 20-34 Faster time to optimized therapy ho
Slide 10: Focused innovation: Prioritising expansion of ASTar capabilities in near-term
Focused innovation | Prioritising expansion of ASTar capabilities in near-term On-market Product 1 to 3 years 3 to 5 years ASTar® • Expanded panel Expansion • Expansion: Isolates BC G- other indications • Expansion: Urine CE-IVDR FDA Cleared Podler® EU/US clinical trials Commercial launch Extended c
Slide 11: Financial highlights: During (and after) second quarter
Financial highlights | During (and after) second quarter • Cost savings program initiated in January now completed, estimated savings amount to SEK 50 million annually, restructuring costs taken in second quarter of SEK 8.4 million • Cost savings already visible in first two quarters but will have f
Slide 12: Consolidated statement of profit and loss: Second quarter
Consolidated statement of profit and loss | Second quarter • Instrument sales and other operating income recorded, SEK 0.6 million (1.9) • Top-line is affected negatively short term by the use of reagent rental model in some European markets such as Italy • In short the reagent rental model has no c
Slide 13: Consolidated statement of financial position: End of second quarter
Consolidated statement of financial position | End of second quarter • Cash and cash equivalents amounted to SEK 20.9 million (81.9) • SEK 41.5 milion in new loan from main owner Nexttobe received in second quarter • SEK 16.7 million average monthy burn rate for the second quarter • SEK 17.1 million
Slide 14: Future financing
Future financing • As of 30 of June we have a total of SEK 80.9 million in available funds, whereof cash at bank 20.9M and 60M in an unutlized loan facility from main owner. • Total loan facility amounts to SEK 101.5 million is now approved at the AGM and will mature 30 June 2026 • Our average month
Slide 15: Thank you!
Thank you! Q-linea aims to contribute to a healthier society by future- proofing a new generation of healthcare professionals, labs and hospitals 15